Professor Katie Watson joins Ethics Talk to consider key questions about clinical and legal risk management for clinicians trying keep patients safe and for patients with complex pregnancies trying to stay alive.
A history of device oversight by the US Food and Drug Administration traces regulatory changes in response to injuries caused by Dalkon Shield intrauterine devices.
AMA J Ethics. 2021;23(9):E712-720. doi:
10.1001/amajethics.2021.712.
Two bioethicists argue that prenatal disability screening promotes negativity toward the disabled and gives parents the ability to selectively form families.
A philosophy professor argues that prenatal genetic testing allows potentially painful afflictions to be discovered prior to birth and does not unjustly discriminate against disabled people.
Despite the natural desire in obstetrics for a happy outcome, sometimes the common aggressive interventions will not help maintain a pregnancy until viability.
Amanda Fakih, MHSA and Kayte Spector-Bagdady, JD, MBE
Testing everyone for everything identifies more fetal conditions, but confusion persists about whether clinicians should leave screening decisions to patients.
AMA J Ethics. 2019;21(10):E858-864. doi:
10.1001/amajethics.2019.858.